A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non-Small Cell Lung Cancer

Brief description of study

If you have been diagnosed with advanced, metastatic, non-small cell lung cancer (NSCLC), you may qualify for this study. The main goal of this study is to test the safety and effectiveness of an investigational drug JNJ-61186372 for treating patients with your type of cancer.

Clinical Study Identifier: s17-01799
ClinicalTrials.gov Identifier: NCT02609776

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.